Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | Any - 17 |
| Updated: | 7/19/2018 |
| Start Date: | July 12, 2018 |
| End Date: | May 2023 |
| Contact: | Zaleski L Zaleski, MD |
| Email: | katherine.zaleski@childrens.harvard.edu |
| Phone: | 6173557737 |
This study will measure plasma concentrations of bivalirudin in pediatric patients undergoing
cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB),
or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices
(LAD). The aim is to understand the pharmacokinetics of bivalirudin in these settings.
cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB),
or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices
(LAD). The aim is to understand the pharmacokinetics of bivalirudin in these settings.
Inclusion Criteria:
- pediatric patient (age less than 18 years)
- weight > 3kg
- scheduled to undergo 1) cardiac catheterization, 2)cardiac surgical procedure
utilizing CPB, and/or 3) the institution of extracorporeal support
- must already require the administration of bivalirudin as part of their treatment plan
Exclusion Criteria:
- Age equal to or greater than 18 years,
- weight less than 3kg
- end-stage renal failure requiring renal replacement therapy.
We found this trial at
1
site
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
